CSL Behring Australia

CSL Behring is a global leader in the biotherapeutics industry, specializing in the development and manufacture of therapies for rare and serious diseases. As the primary business unit of CSL Limited, the company focuses on plasma-derived and recombinant protein therapies to treat conditions such as hemophilia, primary immunodeficiencies, and hereditary angioedema. The company operates one of the world's largest plasma collection networks and maintains significant manufacturing and R&D hubs in Australia, the United States, and Europe. Its portfolio includes market-leading products like Privigen, Hizentra, and the first-ever gene therapy for hemophilia B, Hemgenix. CSL Behring continues to advance a diverse pipeline of monoclonal antibodies and recombinant proteins targeting unmet needs in immunology, hematology, and cardiovascular medicine.